Glucocorticoid-induced enhancement of extinction—from animal models to clinical trials

Dominique de Quervain¹,²,³ · Oliver T. Wolf⁴ · Benno Roozendaal⁵,⁶

Received: 26 June 2018 / Accepted: 6 November 2018 / Published online: 4 January 2019
© The Author(s) 2019

Abstract
Extensive evidence from both animal model and human research indicates that glucocorticoid hormones are crucially involved in modulating memory performance. Glucocorticoids, which are released during stressful or emotionally arousing experiences, enhance the consolidation of new memories, including extinction memory, but reduce the retrieval of previously stored memories. These memory-modulating properties of glucocorticoids have recently received considerable interest for translational purposes because strong aversive memories lie at the core of several fear-related disorders, including post-traumatic stress disorder and phobias. Moreover, exposure-based psychological treatment of these disorders relies on successful fear extinction. In this review, we argue that glucocorticoid-based interventions facilitate fear extinction by reducing the retrieval of aversive memories and enhancing the consolidation of extinction memories. Several clinical trials have already indicated that glucocorticoids might be indeed helpful in the treatment of fear-related disorders.

Keywords Glucocorticoids · Memory · Fear-related disorders · Clinical trials

Introduction
Stress mediators, including hormones, peptides, and neurotransmitters, promote the organism’s ability to cope with stress by acting on target systems in the periphery but also by exerting numerous effects on the brain (Joëls and Baram 2009). In addition to preparing an individual for the acute consequences of dangerous or threatening situations (i.e., fight-flight response) and the return to homeostasis, an important function of the stress response is to induce long-term adaptive responses, including influences on learning and memory (Roozendaal and McGaugh 2011). Notably, stressful and emotionally arousing events are typically remembered better than ordinary events (McGaugh 2003). By contrast, memory retrieval can be hampered during stressful and emotionally arousing conditions (de Quervain et al. 2009, 2017; Wolf 2017).

Extensive evidence from studies in animals have indicated that glucocorticoid hormones, in concert with many other stress mediators, are crucially involved in mediating the modulatory effects of stress on both the consolidation and retrieval of memory (Quirarte et al. 1997; de Quervain et al. 1998; Roozendaal et al. 2009). Furthermore, glucocorticoids are known to interact with arousal-induced noradrenergic activity to selectively modulate memory of emotionally arousing information or during emotionally arousing test situations (de Quervain et al. 2009). Importantly, these modulatory effects of glucocorticoids on emotional memory processes have also been found in studies with healthy humans (de Quervain et al. 2009; Wolf 2009; Schwabe et al. 2012).
It seems highly adaptive to have such biological processes that enable the significance of events to regulate their remembrance (McGaugh 2003; de Quervain et al. 2009). However, in case of extremely aversive events, overly traumatic or fearful memories may contribute to the development and symptoms of fear-related disorders, such as post-traumatic stress disorder (PTSD) and phobias. Current options for treating fear-related disorders mainly consist of exposure-based psychotherapy, which is based on extinction of conditioned fear by re-exposure to trauma- or fear-related memories, and/or anxiety-reducing and antidepressant medications. Psychotherapeutic interventions are generally successful, especially in phobias, but treatment response is diverging and the return of fear is a well-known problem (Bandelow et al. 2007). Exposure therapy is therefore ineffective in a substantial subgroup of over 50% of patients (Bradley et al. 2005; Bandelow et al. 2007; Cusack et al. 2016). Also, current pharmacological treatments such as anxiolytic or antidepressant drugs are far from satisfactory, since many patients continue to have symptoms (Barton et al. 2014). Such treatments primarily relieve stress and anxiety symptoms (Ipser et al. 2006) but do not diminish the underlying aversive memory trace (Lin et al. 2016). Therefore, new therapeutic approaches are desperately needed.

A possible pharmacological approach to prevent PTSD after trauma exposure is to reduce the initial consolidation of memory of aversive events, for example by the use of opioids (Holbrook et al. 2010) or beta-adrenergic receptor blockers (Pitman et al. 2002). Another approach would be to diminish the excessive retrieval of aversive memories, thereby reducing the severity and/or frequency of experienced symptoms such as intrusions and nightmares. Inhibition of memory retrieval during the first days or weeks after a traumatic event may also counteract the progressive formation of an overly strong traumatic memory trace, thus having preventing effects with regard to the development of PTSD. A further approach might consist of aiding the extinction of the traumatic memory trace (a process that is often impaired in patients with fear-related disorders) (Wessa and Flor 2007). This approach might be particularly well suited if the drug treatment is combined with exposure therapy in a timed manner to boost extinction and improve the long-term outcome of exposure therapy.

Here, we reason that glucocorticoid treatment is of special interest for preventing and treating fear-related disorders because they can affect multiple memory processes, i.e., reduce the retrieval of aversive memories and enhance the consolidation of extinction memories, that synergistically contribute to a reduction of fear-related symptoms (Fig. 1).

**Stress, glucocorticoids, and memory**

Stress leads to an activation of the hypothalamus-pituitary-adrenal (HPA) axis. Activation of the HPA axis triggers a cascade of events that induces the release of glucocorticoids (mainly cortisol in humans, corticosterone in rodents) from the adrenal cortex (Ulrich-Lai and Herman 2009). First, corticotropin-releasing factor (CRF) is released by the hypothalamic paraventricular nucleus into the portal system. CRF then induces the release of adrenocorticotropin from the adrenal pituitary gland, which subsequently stimulates the release of glucocorticoids from the adrenal cortex into the bloodstream (Smith and Vale 2006). In the periphery, glucocorticoids exert, for example, immunosuppressive actions and increases in blood glucose levels (Wajchenberg et al. 1984; Sapolsky et al. 2000; Kuo et al. 2015).

In the 1960s and 70s, it was first discovered that glucocorticoids can facilitate the extinction of fear-motivated behaviors (Bohus and Lissak 1968). Many subsequent studies reported both enhancing and impairing properties of glucocorticoids on cognitive performance (Flood et al. 1978; Beckwith et al. 1986; Luine et al. 1993; Arbel et al. 1994; Kirschbaum et al. 1996). More recent studies indicated that glucocorticoids can have opposite effects on distinct memory processes. There is now extensive evidence for the view that glucocorticoids enhance the consolidation of memory of new information, including extinction memory, but impair the retrieval of already stored information (de Quervain et al. 2009; Schwabe et al. 2012). Most of these glucocorticoid effects on specific memory functions have been investigated in conditions with acute elevations of glucocorticoid levels, such as by an acute stressor or single glucocorticoid administration. Although clinical conditions with chronically elevated glucocorticoid levels are usually associated with impaired cognitive performance.
(Sapolsky 2000; McEwen 2001), it became clear that glucocorticoid administration even under such chronic stress conditions often exerts opposite effects on consolidation and retrieval processes. For example, comparable to the memory effects in acute conditions, a single glucocorticoid administration to patients with PTSD or phobias (which are chronic stress conditions) reduces the recall, but enhances the extinction, of fear memories (de Quervain et al. 2009). Furthermore, acute glucocorticoid administration also impairs retrieval processes in patients who have chronically elevated glucocorticoid levels (as a result of medication) (Coluccia et al. 2008). In the following sections, we discuss acute glucocorticoid effects on different memory processes.

**Consolidation**

Memory consolidation refers to a process by which a fragile short-term memory trace is transferred into stable long-term memory (McGaugh 2000). However, not all information is equally well transferred into long-term memory. In fact, it is well recognized that especially emotionally arousing (pleasant or unpleasant) life events are remembered better than neutral events, even after a long period of time (McGaugh 2003). There is compelling evidence from studies in both animals and humans that glucocorticoids are crucially involved in regulating the consolidation of memory processes (Roozendaal 2000; McGaugh and Roozendaal 2002; Het et al. 2005; Sandi and Pinelo-Nava 2007; de Quervain et al. 2009; Roozendaal et al. 2009; Schwabe et al. 2012; de Quervain et al. 2017). Blockade of glucocorticoid production with the synthesis inhibitor metyrapone impairs consolidation processes in both animals and humans (Cordero et al. 2002; Maheu et al. 2004). In contrast, acute systemic glucocorticoid administration enhances long-term memory when given either before (Sandi and Rose 1994; Buchanan and Lovallo 2001; Abercrombie et al. 2003) or shortly after a training experience (Flood et al. 1978; Sandi and Rose 1994; Roozendaal and McGaugh 1996; Roozendaal et al. 1999a). Glucocorticoid manipulations applied before learning may affect both encoding and consolidation processes. Human work has shown that administration of glucocorticoids might affect the encoding of memory by having an influence on both sensory (Miller et al. 2015) and attentional processes (Putman and Roelofs 2011; Hermans et al. 2014). Glucocorticoid effects on memory consolidation follow an inverted U-shaped dose-response relationship: Moderate doses enhance consolidation processes, whereas lower or higher doses are typically less effective or even induce memory impairment (Roozendaal et al. 1999b; Andreano and Cahill 2006).

Some evidence indicates that stress effects on memory consolidation are more pronounced in men than in women (Andreano and Cahill 2006; Preuss and Wolf 2009; Cornelisse et al. 2011), possibly due to an interaction with sex hormones; in particular, hormonal contraceptives can raise cortisol-binding globulin (CBG) concentrations and therefore lead to a blunted free cortisol response (Kirschbaum et al. 1999) and reduce stress effects on memory (Preuss and Wolf 2009; Comelisse et al. 2011; Merz and Wolf 2017). Consistent with these findings, no sex differences in memory effects were reported among people acutely dosed with exogenous cortisol (Buchanan and Lovallo 2001).

Evidence from several kinds of studies indicates that glucocorticoids interact with arousal-induced noradrenergic activity in influencing memory consolidation (Roozendaal and McGaugh 2011). For example, animal model studies have shown that glucocorticoid administration after footshock delivery in an inhibitory avoidance task rapidly augments noradrenaline levels within the basolateral amygdala (McReynolds et al. 2010). On the other hand, attenuation of noradrenergic signaling with a beta-adrenergic receptor antagonist administered systemically or directly into the basolateral amygdala blocks the enhancing effect of glucocorticoids on memory consolidation for emotionally arousing training experiences (Quirarte et al. 1997; Roozendaal et al. 2006). Further, glucocorticoid administration immediately after object recognition training enhances 24-h memory of emotionally aroused rats but not that of rats previously habituated to the training context in order to reduce novelty-induced emotional arousal (Okuda et al. 2004; Roozendaal et al. 2006). However, with such low-arousing conditions, pharmacological reinstatement of (nor)adrenergic activity by the administration of the noradrenergic stimulant yohimbine enables glucocorticoid-induced memory enhancement (Roozendaal et al. 2006). Human studies generally support the conclusion of animal experiments in that glucocorticoids enhance memory consolidation only when their activity is paralleled by emotional arousal (i.e. noradrenergic activity) (Kühlmann and Wolf 2006a; Segal et al. 2014). Cortisol administered shortly before or after training selectively enhances long-term memory of emotionally arousing, but not of emotionally neutral, items (Buchanan and Lovallo 2001; Kühlmann and Wolf 2006a). Moreover, a cold pressor stress in humans (i.e., placing the arm in ice water), a procedure that significantly elevates endogenous cortisol levels, enhances memory of emotionally arousing slides, but does not affect memory of emotionally neutral slides (Cahill et al. 2003; Preuss and Wolf 2009).

Glucocorticoid hormones are highly lipophilic (McEwen et al. 1979) and bind directly to mineralocorticoid receptors (MRs) and glucocorticoid receptors (GRs) in the brain (Reul and de Kloet 1985; Arriaza et al. 1987). MRs have a high affinity for the natural steroids corticosterone, cortisol and aldosterone, whereas GRs have an approximately 10 times lower affinity for corticosterone and cortisol but show a high affinity for the synthetic ligand dexamethasone (Reul et al. 1987; Sutanto and de Kloet 1987). The memory-enhancing
effects of glucocorticoids appear to involve the selective activation of the low-affinity GR (Oitzl and de Kloet 1992; Roozendaal and McGaugh 1997). Some studies, however, indicated that MR function, either alone or in conjunction with GRs, might also be implicated in mnemonic functions (Rimmele et al. 2013; Atucha et al. 2015; Hinkelmann et al. 2015), but in most cases, evidence for a direct influence on consolidation processes is lacking.

Glucocorticoids are known to act through intracellular and intranuclear receptors and can affect neuronal function through their ability to affect gene transcription (Datson et al. 2001). However, glucocorticoids also have various non-genomic actions on neuropsychology and memory, through a membrane-associated variant (or variants) of the steroid receptor (Johnson et al. 2005; Barsegyan et al. 2010; Riedemann et al. 2010; Roozendaal et al. 2010; Lee et al. 2011). Activation of these membrane steroid receptors results in effects such as a rapid increase in glutamate-release probability from presynaptic sites (Karst et al. 2005) and rapid insertion of AMPA-receptor subunits into postsynaptic membranes (Conboy and Sandi 2010; Krugers et al. 2010). Several experimental findings have shown that glucocorticoids affect on increasing noradrenergic signaling also have an onset that is too fast to be mediated via transcriptional regulation in the nucleus and likely involve a rapid, non-genomic mode of action. Glucocorticoids and noradrenaline signaling mechanisms might act synergistically to rapidly enhance AMPA-receptor function (Zhou et al. 2012) as well as to influence several other molecular events—for example, such interactions may induce rapid phosphorylation of the transcription factor cAMP-responsive element-binding protein (CREB) which, after binding to CREB-binding protein (CBP), promotes associated epigenetic mechanisms such as histone acetylation (Roozendaal et al. 2010; Chen et al. 2012). A recent study indicated that a moderate dose of glucocorticoids combined with noradrenergic stimulation caused a transient enhancement of glutamatergic transmission within the basolateral amygdala, but that this time window of excitability was extended in conditions mimicking severe stress (Karst and Joëls 2016). These genomic and non-genomic glucocorticoid actions may ultimately, and collectively, result in neuroplasticity and structural changes, e.g., via modifications of cell-adhesion molecules, and strengthen cell-cell interactions (Sandi 2011).

Recent findings indicate that the actions of glucocorticoids on memory consolidation also involve intriguing rapid signaling interactions with the endocannabinoid system (Campolongo et al. 2009). Endogenous ligands for cannabinoid receptors, endocannabinoids, are synthesized on demand from lipid precursors in the postsynaptic membrane, and serve as retrograde messengers at both excitatory and inhibitory neurotransmission (Kano 2014) and therefore are key players in fine-tuning neural activity (Ohno-Shosaku and Kano 2014). The endocannabinoid system is closely linked to the glucocorticoid stress system (Hill et al. 2010; Atsak et al. 2012; Morena et al. 2015), and emerged as a key modulator of the stress response (Hill et al. 2010; Morena et al. 2015), emotion regulation (Evanston et al. 2010; Marco and Laviola 2012) and emotional memory (Morena et al. 2016). Most importantly, it was found that a cannabinoid type-1 (CB1) receptor antagonist administered into the basolateral amygdala blocks the ability of glucocorticoids to facilitate aversive memory consolidation (Campolongo et al. 2009; Atsak et al. 2015). Acute glucocorticoid administration or training on an emotionally arousing task rapidly increases endocannabinoid levels in the amygdala as well as in other brain regions such as the hippocampus and prefrontal cortex (Adams et al. 2003; Hill et al. 2010; Morena et al. 2014). The findings suggest that glucocorticoids might bind to a membrane-located receptor that activates a G protein-coupled signaling cascade inducing endocannabinoid synthesis (Di et al. 2016). Endocannabinoid ligands then could diffuse and bind to presynaptic CB1 receptors. What the endocannabinoids will do next is unclear at this time. Possibly, endocannabinoids target local GABAergic terminals to inhibit GABA release onto noradrenergic terminals (Di et al. 2016), thus increasing the local release of noradrenaline (Fig. 2).

**Retrieval**

Memory retrieval refers to the mental process of recollecting information from the past. In contrast to the enhancing effects of glucocorticoids on memory consolidation, stress exposure or glucocorticoid administration to rats or mice shortly before retention testing impairs the retrieval of memory (de Quervain et al. 1998). Although the vast majority of studies have investigated the effects of stress and glucocorticoids on the retrieval of hippocampus-dependent forms of memory in contextual fear conditioning and spatial water-maze tasks, some animal model studies have shown that stress exposure or glucocorticoid administration before retention testing also impairs the retrieval of cortex-dependent recognition memory (Barsegyan et al. 2015) and striatum-dependent stimulus-response associations (Atsak et al. 2016). These temporary effects of glucocorticoids on memory retrieval impairment (the effects dissipate when glucocorticoid levels have returned to baseline) are rapidly induced and do not seem to depend on gene transcription (Sajadi et al. 2006) and might selectively depend on the membrane GR (Chauveau et al. 2010) and being mediated via non-genomic actions (Roozendaal et al. 2004). Glucocorticoid-induced impairment of memory retrieval may help to suppress behaviors that are no more relevant or even maladaptive and a more opportune coping response is required (de Kloet et al. 1999). This mechanism is...
especially important in situations when the organism is forced to adapt to a changed environment.

Highly comparable to these findings in animal models, stress exposure or glucocorticoid administration also impairs retrieval processes in humans. A single administration of cortisol (at a dose resulting in high physiological cortisol levels) 1 h before retention testing impaired the recall of words learned 24 h earlier (de Quervain et al. 2000). Moreover, increased cortisol levels due to psychological stress have also been shown to impair declarative memory retrieval (Domes et al. 2004; Kuhlmann et al. 2005b; Buchanan et al. 2006; Shields et al. 2017). Glucocorticoid effects on memory retrieval are highly comparable to those seen in studies investigating memory consolidation in that the effects depend on emotional arousal. Specifically, it has been shown in studies in humans that the retrieval of emotionally arousing information is also particularly sensitive to impairment by glucocorticoids (de Quervain et al. 2000; Wolf et al. 2001; Buss et al. 2004; Het et al. 2005; Kuhlmann et al. 2005a, b; Smeets et al. 2005; Buchanan et al. 2006; Kuhlmann and Wolf 2006b; de Quervain et al. 2007; Smeets et al. 2008; Schwabe et al. 2009; Tollenaar et al. 2009). Glucocorticoid effects on memory retrieval also depend critically on noradrenergic activity within the brain (de Quervain et al. 2007; Schwabe et al. 2009). The influence of glucocorticoid–noradrenergic interactions on memory retrieval was further shown to also depend on the endocannabinoid system (Atsak et al. 2012a; Morena et al. 2015). Also comparable to memory consolidation, stress effects on memory retrieval are more prominent in men than in women who use hormonal contraceptives (Kuhlmann and Wolf 2005), suggesting possible interactions with sex hormones (Merz and Wolf 2017).

Extinction

Extinction is a process in which conditioned responses to a stimulus previously paired with an aversive event diminish if the conditioned stimulus is presented repeatedly without the reinforcing stimulus (Quirk and Mueller 2008). Like other forms of learning, extinction learning is followed by a consolidation phase. Whereas the consolidation of extinction memory and that of new memory show partially distinct molecular and neuroanatomical profiles (e.g., different role of the prefrontal cortex) (Milad and Quirk 2012), glucocorticoids seem to play a similar role in both. Animal models have shown that glucocorticoid administration enhances the consolidation of extinction memory (Barrett and Gonzalez-Lima 2004; Cai et al. 2006; Yang et al. 2006; Blundell et al. 2011) whereas a suppression of glucocorticoid signaling impairs extinction consolidation (Bohus and Lissak 1968; Barrett and Gonzalez-Lima 2004; Yang et al. 2006; Blundell et al. 2011; Clay et al. 2011). More specifically, glucocorticoids administered either before or after extinction learning modify extinction processes of several types of fear memory, including auditory fear conditioning (Barrett and Gonzalez-Lima 2004), contextual fear conditioning (Cai et al. 2006; Blundell et al. 2011) and fear-potentiated startle (Yang et al. 2006), and in the predator stress paradigm (Clay et al. 2011). Furthermore, direct administration of the GR agonist dexamethasone into the amygdala prior to extinction training was found to enhance extinction memory (Yang et al. 2006).

Current theories of extinction learning postulate that during extinction a safety memory trace is established since the stimulus is no longer followed by an aversive event. The ‘competition’ between the original fear memory trace and the safety memory trace acquired during extinction can explain the well-documented recovery phenomena of spontaneous recovery.
reinstatement, and renewal (Vervliet et al. 2013). Extinction is thought to be more context dependent than the originally acquired fear memory (Bouton et al. 2006). In the laboratory, this context dependency can be studied using a renewal paradigm where acquisition takes place in context A, extinction learning in context B, and extinction retrieval is tested in both contexts A and B. Typically, the return of fear is stronger in the acquisition context (A). This mechanism might underlie the return of fear after a (seemingly) successful extinction-based therapy (e.g., when a patient again encounters a spider at home). In a series of human studies, the impact of stress on extinction and renewal was investigated using a contextual fear conditioning paradigm originally developed by Milad and colleagues (Milad et al. 2007). Stress (the Socially Evaluated Cold Pressor Test) induced 25–30 min before extinction learning enhanced the consolidation of extinction memory and made it less context dependent as evident by a reduced renewal effect (Meir Drexler et al. 2018) (Fig. 3). In contrast, stress induced immediately after extinction learning made the extinction memory more context dependent (Hamacher-Dang et al. 2015). Thus, from a clinical perspective, stress induction or cortisol administration should occur before extinction training in order to create a stronger and less context-dependent extinction memory trace. In a recent pharmacological functional MRI (fMRI) study (Merz et al. 2018), cortisol administered before extinction diminished activation of the amygdala-hippocampal neural network at the beginning of extinction and enhanced functional connectivity of the anterior parahippocampal gyrus with the ventromedial prefrontal cortex (vmPFC), a brain region crucially involved in extinction processes (Milad and Quirk 2002). These network alterations may underlie the blocking effects of cortisol on the retrieval of the initial fear memory and its combination with the beneficial effects on the consolidation of fear extinction memory (Nakataki et al. 2017).

The long-term efficacy of extinction-based therapies is not only determined by the initial extinction success, but also by the ability to retrieve the extinction memory when encountering the previously feared stimulus again (e.g., when meeting a spider at home in the cellar) (Quirk and Mueller 2008). In this situation, the initial fear memory trace and the inhibitory extinction memory trace have to compete and the ‘winner’ determines the actual behavioral response. Hence, the question arises how stress or glucocorticoids influence the retrieval of extinction memory. Two recent studies provided first evidence that acute stress can impair extinction retrieval in humans. In one study, a predictive learning task was used (Hamacher-Dang et al. 2013) while the other study used a classical fear conditioning paradigm (Raio et al. 2014). In both studies, stress was associated with a return of the originally learned behavior (or emotion). Supporting findings have been obtained in rodent models (Deschaux et al. 2013). However, conflicting findings have been reported as well (Merz et al. 2014). Similar findings have been reported after pharmacological glucocorticoid administration. In two independent fMRI studies, it was reported that cortisol administered before extinction recall testing induced a return of fear of the previously extinguished response (Kinnaer et al. 2016; Kinnaer et al. 2018). This was associated with reduced activity of the vmPFC (Kinnaer et al. 2016) and enhanced signaling in the amygdala (Kinnaer et al. 2018). Interestingly, this effect was absent in women using hormonal contraceptives, again pinpointing to a modulatory influence of sex hormones.

Taken together, the laboratory findings obtained so far suggest that glucocorticoids can facilitate extinction when given before extinction training (in line with the model proposed above (Fig. 1)). In contrast, elevated glucocorticoid concentrations at times of extinction retrieval might cause a return of fear by impairing extinction recall.

**Clinical implications**

Based on the evidence from basic animal model and human studies reviewed above, glucocorticoids could be administered at different time points to reduce fear in clinical conditions. Glucocorticoids could be administered to diminish the retrieval of aversive memories, thereby reducing the expression of fear, such as of reexperiencing the traumatic event in PTSD. It is important to note that a reduced recall of aversive memories may also support fear extinction: Experiencing reduced fear in otherwise fearful situations is likely to support fear extinction processes by promoting non-fearful, corrective

---

**Fig. 3** Stress before extinction learning reduced the return of fear in a renewal paradigm. The renewal test compared the mean skin conductance response (SCR) to the conditioned stimuli (CS+) in both contexts A (acquisition context) and B (extinction context). The control group (left panel; n = 20) showed renewal of the extinguished fear response (**P < .001**: the response to the previously extinguished CS+ in context A is higher than in context B), the stress (socially evaluated cold pressor test 25–30 min before extinction learning) group (right panel; n = 20) showed no renewal. These results suggest a stronger and more generalized extinction memory in the stress group. Error bars represent SEM and thus between-subject variance. CS+, conditioned stimulus. Adapted from (Meir Drexler et al. 2018)
Low cortisol levels depend on several factors, including genetic predisposition and the use of certain medications such as serotonin- or noradrenaline-reuptake inhibitors, which did not find beneficial effects of cortisol treatment (10 mg or 30 mg per day for 1 month) diminished re-experiencing symptoms, interrupting the vicious cycle of spontaneous retrieving, re-experiencing and reconsolidating traumatic memories in PTSD and, thereby, promote forgetting, a spontaneous process that occurs when memory is not reactivated. Furthermore, high cortisol levels at the time of confrontation with an aversive cue may facilitate the extinction of aversive memory. Two mechanisms may contribute to this facilitation: (i) because of the cortisol-induced reduction of memory retrieval, an aversive cue is no longer followed by the usual aversive memory retrieval and related clinical symptoms but, instead, becomes associated with a non-aversive experience, which is stored as extinction memory; (ii) glucocorticoids can facilitate the consolidation of memory of these corrective experiences.

Clinical trials investigating the effects of glucocorticoid treatment on extinction memory have found that such treatment indeed facilitates extinction processes (Aerni et al. 2004; Suris et al. 2010; Yehuda et al. 2010; Yehuda et al. 2015). In particular, a recent randomized, double-blind, placebo-controlled trial in 24 PTSD veterans reported that the administration of cortisol (30 mg) combined with exposure treatment improved treatment retention and outcome (Yehuda et al. 2015). Moreover, a significant treatment condition by responder status interaction for glucocorticoid sensitivity indicated that responders to cortisol augmentation had the highest pre-treatment glucocorticoid sensitivity that diminished over the course of treatment (Yehuda et al. 2015).

Several studies have used high-dose glucocorticoid administration for a longer time period (typically several days) in the aftermath of a traumatic event. Here, glucocorticoids likely affected several memory phases. These studies indicate that prolonged treatment with high doses of cortisol that started within 12 h after trauma reduces the risk for the development of later PTSD (Schelling et al. 2001, 2004; Weis et al. 2006; Delahanty et al. 2013). A potential mechanism might be that high doses of glucocorticoids—due to the inverted-U-shaped dose-response relationship for the effects of glucocorticoids on consolidation—may have resulted in an impairment of consolidation (Roozendaal et al. 1999b), and/or by a reduction of the retrieval of the traumatic memory and thereby interrupting the vicious cycle of retrieving, re-experiencing and reconsolidating aversive memories (de Quervain et al. 2009). These effects of glucocorticoid administration on reducing the risk for the development of PTSD are consistent with the findings of other studies indicating that the risk for PTSD is decreased by higher excretion of endogenous cortisol in the first hours after a traumatic event (McFarlane et al. 1997; Yehuda et al. 1998; Delahanty et al. 2000).

Recently, two systematic reviews suggested that the prolonged administration of glucocorticoids after a traumatic event is the most effective pharmacological intervention currently available for the prevention of PTSD (Amos et al. 2014; Sijbrandij et al. 2015). One review included seven randomized controlled trials investigating the efficacy of several pharmacological treatments (4 with cortisol, 3 with the beta-adrenergic receptor antagonist propranolol, one with the selective serotonin-reuptake inhibitor escitalopram and one with the benzodiazepine temazepam). The authors found that...
| Drug | Design | Timing and duration | Memory phase exposed | Outcome | Refs |
|------|--------|---------------------|----------------------|---------|------|
| Cort | DB, PC, CO | Daily for 30 days | Retrieval | ↓ Intrusions while under treatment | Aerni et al. 2004 |
| Cort | DB, PC, CO | Daily for 7 days | Retrieval | No change in intrusions while under treatment | Ludascher et al. 2015 |
| Cort | RCT | Single dose after exposure | Extinction | ↓ PTSD symptoms at 1 week | Suris et al. 2010 |
| Cort | RCT | 20 min before exposure therapy, on 8 days | Retrieval and extinction | ↓ PTSD symptoms at 6 weeks | Yehuda et al. 2015 |
| Cort | RCT | Starting < 12 h after trauma, for 10 days | Consolidation and retrieval | ↓ PTSD symptoms at 3 months | Delahanty et al. 2013 |
| Cort | RCT | Starting < 6 h after trauma, for 6 days | Consolidation and retrieval | ↓ PTSD incidence at 31 months | Schelling et al. 2001 |
| Cort | RCT | Starting < 6 h after trauma, for 4 days | Consolidation and retrieval | ↓ Stress scores at 6 months | Schelling et al. 2004 |
| Cort | RCT | Starting < 6 h after trauma, for 4 days | Consolidation and retrieval | ↓ Stress scores at 6 months | Weis et al. 2006 |
| Cort | RCT | Single dose < 6 h after trauma | Consolidation | ↓ PTSD incidence at 3 months | Zohar et al. 2011 |
| Dex  | RCT | Single intraoperative dose | Consolidation | No difference in PTSD incidence at 18 months | Kok et al. 2016 |
| Cort | RCT | Single dose 1 h before phobic stimulus | Retrieval | ↓ Fear while under treatment | Soravia et al. 2006 |
| Cort | RCT | 1 h before phobic stimulus, on 4 days | Retrieval and extinction | ↓ Fear while under treatment | Soravia et al. 2006 |
| Cort | RCT | 1 h before exposure therapy, on 2 days | Retrieval and extinction | ↓ Fear at 1 month | Soravia et al. 2014 |
| Cort | RCT | 1 h before exposure therapy, on 3 days | Retrieval and extinction | ↓ Fear at 1 month | de Quervain et al. 2011 |

Only randomized controlled trials (RCT) or double-blind (DB), placebo-controlled (PC), cross-over (CO) trials are included. Cort: Cortisol; Dex: Dexamethasone. Adapted from (de Quervain et al. 2017)
cortisol, but none of the other drugs, showed efficacy in reducing the risk for PTSD in adult patients (Amos et al. 2014). The other review included 5 placebo-controlled studies with cortisol and reported a large effect of cortisol in preventing PTSD (Sijbrandij et al. 2015). Currently, there are several ongoing trials investigating the effects of cortisol administration on the development of PTSD (NCT00855270 https://clinicaltrials.gov/ct2/show/NCT00855270?term=NCT00855270&rank=1),(NCT02402114 https://clinicaltrials.gov/ct2/show/NCT02402114?term=NCT02402114&rank=1) and on fear extinction in veterans with PTSD (NCT00674570 https://clinicaltrials.gov/ct2/show/NCT00674570?term=NCT00674570&rank=1).

Human genetic and epigenetic studies have found several alterations in the glucocorticoid system associated with PTSD risk. NR3C1 alterations. The BclI polymorphism, a C to G nucleotide change associated with receptor hypersensitivity to glucocorticoids and lower plasma cortisol levels, is a single nucleotide polymorphism of the GR gene (NR3C1, nuclear receptor subfamily 3, group C, member 1 (van Rossum et al. 2003). Studies in healthy humans have indicated that GG carriers (as compared to GC and CC carriers) of the BclI polymorphism show enhanced emotional memory (Ackermann et al. 2013), and increased incidence of traumatic memories in patients who underwent intensive care therapy (Hauer et al. 2011). Furthermore, increased expression of NR3C1 in peripheral blood mononuclear cells has been found to be related to higher PTSD risk, which is in line with the enhanced GR feedback found in PTSD patients (van Zuiden et al. 2011). Moreover, there is evidence that these alterations are partly epigenetically controlled. Two recent studies found that methylation of the NR3C1 promoter is inversely related with lifetime PTSD risk (Labonte et al. 2013; Yehuda et al. 2014). Further, a study in genocide survivors reported that decreased methylation at the NGFIA (nerve growth factor-induced protein A) binding site of the NR3C1 promoter is related with increased traumatic memories and increased PTSD risk (Vukojevic et al. 2014). In support of the idea that methylation level of the GR gene might regulate memory processes, this study also found that decreased methylation at the NGFIA binding site of healthy individuals was associated with enhanced picture recognition memory and related brain activity. Together, these studies point to an epigenetic and genetic link between the predisposition to form strong aversive memories and the risk for PTSD. FKBP5 alterations. FKBP5 is known to act as a co-chaperone that modulates GR activity (Zannas et al. 2016). Common alleles of FKBP5 have been related to differences in GR sensitivity, PTSD risk, and the incidence of intrusive memories of aversive photographs (Mehta et al. 2011; Cheung and Bryant 2015). Furthermore, allele-specific demethylation of FKBP5 has been reported to mediate gene–childhood trauma interactions. Specifically, demethylation of FKBP5 was associated with increased stress-dependent gene transcription, followed by a dysregulation of the HPA axis and cortisol levels (Klengel et al. 2013). FKBP5 alleles may also influence exposure-based psychotherapy in PTSD (Wilker et al. 2014), and FKBP5 allele-specific alterations in methylation have been associated with differential responses to psychological treatments for anxiety disorders (Roberts et al. 2015). Taken together, the findings indicating that genetic and epigenetic variations in the glucocorticoid system are associated with aversive and traumatic memory, the risk for PTSD and treatment response, help to better understand the basis of individual differences in risk or resilience for PTSD. It is important to note, however, that common genetic polymorphisms, which typically have small effect sizes, cannot be used for diagnostic and/or personalized treatment purposes. More research is needed to evaluate whether rare genetic variants or specific methylation events might be better suited for such purposes.

With regard to the importance of the endocannabinoid system, which as indicated interacts with glucocorticoids in regulating emotional memory (Campolongo et al. 2009), two studies have suggested that a polymorphism (rs1049353) of the CB1 receptor gene (CNR1) is associated with PTSD risk (Lu et al. 2008; Mota et al. 2015). Furthermore, stimulation of CB1 receptors promotes memory extinction (for review, see de Bitencourt et al. 2013), and first clinical evidence suggests that cannabinoids might be useful in the treatment of PTSD (Roitman et al. 2014; Jetly et al. 2015). Thus, there is now evidence from independent studies indicating that the glucocorticoid and endocannabinoid systems are involved in extinction memory and that these two systems might be promising targets for pharmacological intervention aimed at the prevention and/or treatment of PTSD. In particular, the evidence discussed above indicating that these two systems crucially interact suggests that considering both systems together might bear a large clinical potential. In line with this idea, both systems have been found altered in PTSD (Yehuda 2002; Neumeister et al. 2013). Most interestingly, the combined analysis of glucocorticoid and endocannabinoid markers was shown to have a higher predictive value for classifying PTSD than the individual analyses (Neumeister et al. 2013). Therefore, pharmacological interventions considering both glucocorticoid- and cannabinoid signaling might be promising and should be further investigated in animal and human models of fear learning and extinction to inform future clinical studies (de Bitencourt et al. 2013).

Phobias

Glucocorticoid effects on aversive memory processing may not be restricted to traumatic memories in PTSD, but may also include fear memories in phobia. Several studies have investigated the effects of glucocorticoids on fear symptoms in phobic patients. In a randomized controlled trial in 40 patients with social phobia, a single oral dose of cortisol (25 mg) was
given 1 h before patients were exposed to the Trier Social Stress Test. As compared to placebo, glucocorticoid treatment significantly reduced stress-induced fear, possibly by affecting memory retrieval processes (Soravia et al. 2006). Importantly, in placebo-treated subjects, the stress-induced release of cortisol was negatively correlated with fear ratings, suggesting that endogenously released cortisol might buffer or counteract fear symptoms in patients with social phobia (Soravia et al. 2006). In another randomized, controlled trial with 20 patients with spider phobia, 10 mg oral cortisol 1 h before the repeated exposure to spider photographs resulted in a gradual reduction of stimulus-induced fear (Soravia et al. 2006). This fear reduction was observed even 2 days after the last drug administration, indicating that glucocorticoids might also have facilitated the extinction of phobic fear.

Because fear extinction is the basis of successful exposure therapy in phobic patients, glucocorticoids might be suited to support this process. One randomized, controlled trial in patients with fear of heights examined whether the administration of glucocorticoids before exposure therapy might enhance treatment outcome (de Quervain et al. 2011). Cortisol (20 mg) or placebo was administered to 40 patients 1 h before each of three virtual-reality exposure sessions. As compared to placebo, cortisol led to a significantly greater reduction of fear of heights at posttreatment and at follow-up (Fig. 4). Moreover, patients receiving the glucocorticoid showed a significantly smaller exposure-induced increase in skin conductance level at follow-up (de Quervain et al. 2011). Another study in subjects with fear of spiders found that the combined administration of cortisol and group exposure therapy enhanced treatment outcome (Soravia et al. 2014). Since these studies indicate that the administration of cortisol has beneficial effects on exposure therapy, also endogenous differences in cortisol levels may have an impact on the outcome of this therapy. This possibility was tested in a study investigating if circadian fluctuations in endogenous cortisol levels affect treatment outcome (Lass-Hennemann and Michael 2014). Patients with fear of spiders who were treated with a single exposure session early in the morning (when cortisol levels are high) showed a significantly greater suppression of fear after treatment than did patients who were treated in the evening (when cortisol levels are low). These effects persisted even at a 3-months follow-up. In line with these findings, a further study showed that time-of-the-day-dependent differences in the outcome of exposure therapy are mediated by differences in cortisol levels (Meuret et al. 2016). In conclusion, cortisol is likely to reduce symptoms of phobic fear by reducing aversive memory retrieval and enhancing memory extinction. Therefore, glucocorticoids seem to be well-suited to be administered before extinction-based exposure therapy to support treatment outcome.

**Addiction and other psychiatric disorders**

The beneficial effects of glucocorticoids may also expand to other psychopathologies, in which memory, either in symptomatology or therapy, plays a role. In drug addiction, for example, memory plays a role in the storage of associations that provide the powerful incentives for drug taking that produce cravings (Robinson and Berridge 2000; Kelley 2004; Tiffany and Wray 2012; Preller et al. 2013). A recent randomized, controlled trial reported that a single administration of cortisol (20 mg) reduced craving in patients addicted to low-dose heroin (Walter et al. 2015). It is possible that cortisol might have reduced craving by reducing retrieval of addiction

---

**Fig. 4** Glucocorticoids enhance extinction-based psychotherapy. a VR exposure to fear of heights. b Adding cortisol to VR exposure results in reductions of self-reported fear of heights (measured with Acrophobia Questionnaire, range 0–120) at posttreatment and at follow-up. VR exposure took place on 3 treatment sessions between pretreatment and posttreatment assessment. Cortisol (20 mg) was administered 1 h before each VR exposure session. Values are depicted as mean and SEM. Asterisks (*, \( P < 0.05 \)) indicate significant differences between the placebo- and cortisol group at a certain time point. Adapted from (de Quervain et al. 2011)
memory. However, it has been also reported that the administration of the GR antagonist mifepristone for 1 week decreases alcohol seeking in alcohol-dependent individuals (Vendruscolo et al. 2015).

Furthermore, glucocorticoids might be tested in other psychiatric disorders, in which extinction-based exposure therapy is used, such as in obsessive-compulsive disorder. In this disorder, fear extinction seems to be impaired, which might explain that exposure therapy is difficult and less successful than in phobias (Milad et al. 2013). Therefore, a pharmacological intervention supporting the outcome of exposure therapy of obsessive-compulsive disorder would be highly welcome.

Conclusions and future perspectives

A wealth of studies has shown that glucocorticoids play a critical role in influencing the consolidation, retrieval, and extinction of emotional memories. Because these memory processes are all highly relevant in the pathogenesis, maintenance and treatment of fear-related disorders, the memory-modulatory properties of glucocorticoids are of considerable translational interest.

Many of the clinical trials reviewed above suggest that the strategy to enhance extinction-based psychotherapy with a timed glucocorticoid administration is a particularly promising approach to treat fear-related disorders. Glucocorticoids may unfold synergistic actions that involve a weakening of dysfunctional memories (through reduced memory retrieval) and a strengthening of psychotherapy-related memories of safety (through enhanced memory extinction). Moreover, several studies have indicated that glucocorticoids may be helpful in preventing the development of PTSD when administered in high doses in the aftermath of a traumatic event.

It is important to note that the existing evidence for the usefulness of glucocorticoids in the prevention and treatment of fear-related disorders comes from rather small proof-of-concept studies. Therefore, large randomized, controlled clinical trials are urgently needed. Furthermore, several open questions should be addressed in future basic and clinical studies. For example, it is still not known what the optimal dosage, time point and duration of glucocorticoid treatment are. Also, safety aspects of such treatments must be assessed in detail. Furthermore, the effects of glucocorticoid administration on context dependency and renewal of exposure therapy have not been investigated in clinical settings.

With regard to dosage, studies investigating PTSD-protective effects of hydrocortisone treatment have used between 20 mg (low dose) and 100 mg (high dose) of cortisol/day administered within 6–12 h after a traumatic event (low dose up to 10 days, high dose 1 to 4 days) (Schelling et al. 2001, 2004; Weis et al. 2006; Zohar et al. 2011; Delahanty et al. 2013). Studies in phobias used single or repeated (up to 4 times) administrations of low doses (10–25 mg) of cortisol (Soravia et al. 2006; de Quervain et al. 2011; Soravia et al. 2014). With regard to safety, potential side effects of glucocorticoids have to be considered. Side effects can typically occur under moderate-to-high dose (30–100 mg) cortisol treatment and the risk increases with prolonged administration or after abrupt offset of such treatments due to suppression of the adrenal response (Stanbury and Graham 1998; Henzen et al. 2000).

It is of great interest to investigate if glucocorticoids have beneficial effects also in other neuropsychiatric disorders, in which memory plays a role in symptomatology or treatment, such as obsessive-compulsive disorder. Further studies might also want to search for epigenetic and genetic markers for diagnostic and/or personalized treatment purposes. Biologically based precision medicine in psychiatry is just beginning to be adopted (Insel and Cuthbert 2015), but such an approach might be indispensable for the identification of patients who are most likely to respond to targeted treatments (Ressler 2018). A recent systemic review provided preliminary evidence that pre-treatment biomarkers, including glucocorticoid sensitivity and metabolism, were able to predict the outcome of psychotherapy of PTSD (Colvonen et al. 2017). Future studies should therefore investigate whether patients with HPA-axis alterations or dysfunctional glucocorticoid signaling might particularly benefit from pharmacological glucocorticoid treatment. Furthermore, basic research might investigate new ways of modulating glucocorticoid signaling to identify more-specific and safe glucocorticoid-related drugs. To conclude, the field of stress and memory research is one of the very few areas in neuroscience where knowledge gained from basic studies have translated into direct clinical applications and it will hopefully continue to do so in the future.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

Abercrombie HC, Kalin NH, Thurow ME, Rosenkranz MA, Davidson RJ (2003) Cortisol variation in humans affects memory for emotionally laden and neutral information. BehavNeurosci 117:505–516

Ackermann S, Heck A, Rasch B, Papassotiropoulos A, de Quervain DJ (2013) The BclI polymorphism of the glucocorticoid receptor gene
is associated with emotional memory performance in healthy indi-
viduals. Psychoneuroendocrinology 38:1203–1207

Adams F, Grassie M, Shahid M, Hill DR, Henry B (2003) Acute oral
dexamethasone administration reduces levels of orphan GPCR
glucocorticoid-induced receptor (GIR) mRNA in rodent brain: po-
tential role in HPA-axis function. Mol Brain Res 117:39–46

Aerni A, Traber R, Hock C, Roозendaal B, Schelling G, Papassotiropoulos
A, Nitsch RM, Schnyder U, de Quervain DJ (2004) Low-dose cortisol
for symptoms of posttraumatic stress disorder. Am J Psychiatry 161:
1488–1490

Amos T, Stein DJ, Ipser JC (2014) Pharmacological interventions for
preventing post-traumatic stress disorder (PTSD). Cochrane
Database Syst Rev 7:CD006239

Andreano JM, Cahill L (2006) Glucocorticoid release and memory con-
solidation in men and women. Psychol Sci 17:466–470

Arbel I, Kadar T, Silberman M, Levy A (1994) The effects of long-term
adrenocortical hormones and avoidance be-

Atsak P, Hauer D, Campolongo P, Schelling G, McGaugh JL, Roozendaal
B (2012a) Glucocorticoids interact with the hippocampal
endocannabinoid system in impairing retrieval of contextual fear
memory. Proc Natl Acad Sci U S A 109:3504–3509

Atsak P, Roozendaal B, Campolongo P (2012b) Role of the
endocannabinoid system in regulating glucocorticoid effects on
memory for emotional experiences. Neuroscience 204:104–116

Atsak P, Hauer D, Campolongo P, Schelling G, Fornari RV, Roozendaal
B (2015) Endocannabinoid signaling within the basolateral amygdala integrates multiple stress hormone effects on memory consolidation.
Neuropsychopharmacology 40:1485–1494

Atsak P, Guenzel FM, Kantar-Gok D, Zalachoras I, Yargicoglu P, Meijer
OC, Quiarate GL, Wolf OT, Schwabe L, Roozendaal B (2016)
Glucocorticoids mediate stress-induced impairment of retrieval of
stimulus-response memory. Psychoneuroendocrinology 67:207–
215

Atucha E, Zalachoras I, van den Heuvel JK, van Weert LT, Melchers D,
Mol IM, Belanoff JK, Houtman R, Hunt H, Roozendaal B, Meijer
OC (2015) A mixed glucocorticoid/mineralocorticoid selective
modulator with dominant antagonism in the male rat brain.
Endocrinology 156:4105–4114

Bandelow B, Seidler-Brandler U, Becker A, Wedekind D, Ruther E
(2007) Meta-analysis of randomized controlled comparisons of psy-
chopharmacological and psychological treatments for anxiety disor-
ders. World J Biol Psychiatry 8:175–187

Barrett D, Gonzalez-Lima F (2004) Behavioral effects of metyrapone on
Pavlovian extinction. Neurosci Lett 371:91–96

Barsegyan A, Mackenzie SM, Kurose BD, McGaugh JL, Roozendaal B
(2010) Glucocorticoids in the prefrontal cortex enhance memory consolidation and impair working memory by a common neural mechanism. Proc Natl Acad Sci U S A 107:16655–16660

Barsegyan A, Atsak P, Hornberger WB, Jacobson PB, van Gaalen MM,
Roozendaal B (2015) The vasopressin 1b receptor antagonist A-988315 blocks stress effects on the retrieval of object-
recognition memory. Neuropsychopharmacology 40:1979–1989

Barton S, Kamer C, Salih F, Baldwin DS, Edwards SJ (2014) Clinical
effectiveness of interventions for treatment-resistant anxiety in older
people: a systematic review. Health Technol Assess 18:1–59 v-vi

Beckwith BE, Petsos TV, Scaglione C, Nelson J (1986) Dose-dependent
effects of hydrocortisone on memory in human males. Physiol
Behav 36:283–286

Blundell J, Blais CA, Lagace DC, Eisch AJ, Powell CM (2011) Block of
glucocorticoid synthesis during re-activation inhibits extinction of
an established fear memory. Neurobiol Learn Mem 95:453–460

Bohus B, Lissak K (1968) Adrenocortical hormones and avoidance be-

Bouton ME, Westbrook RF, Corcoran KA, Maren S (2006) Contextual
and temporal modulation of extinction: behavioral and biological
mechanisms. Biol Psychiatry 60:352–360

Bradley R, Greene J, Russ E, Dutra L, Westen D (2005) A multidimen-
sional meta-analysis of psychotherapy for PTSD. Am J Psychiatry
162:214–227

Buchanan TW, Loyało WR (2001) Enhanced memory for emotional
material following stress-level cortisol treatment in humans. Psychoneuroendocrinology 26:307–317

Buchanan TW, Tranel D, Adolphs R (2006) Impaired memory retrieval
correlates with individual differences in cortisol response but not
autonomic response. Learn Mem 13:382–387

Buss C, Wolf OT, Witt J, Hellhammer DH (2004) Autobiographic mem-
ory impairment following acute cortisol administration.
Psychoneuroendocrinology 29:1093–1096

Cahill L, Gorski L, Le K (2003) Enhanced human memory consolidation with post-learning stress: interaction with the degree of arousal at
encoding. Learn Mem 10:270–274

Cai WH, Blundell J, Han J, Greene RW, Powell CM (2006) Postreactivation glucocorticoids impair recall of established fear
memory. J Neurosci 26:9560–9566

Campolongo P, Roozendaal B, Trezza V, Hauer D, Schelling G, McGaugh JL, Cuomo V (2009) Endocannabinoids in the rat
basolateral amygdala enhance memory consolidation and enable glucocorticoid modulation of memory. Proc Natl Acad Sci U S A
106:4888–4893

Chauveau F, Tromeche C, Pierard C, Liscia P, Drouet J, Coutan M,
Beraochea D (2010) Rapid stress-induced corticosterone rise in the
hippocampus reverses serial memory retrieval pattern. Hippocampus 20:196–207

Chen DY, Bambah-Mukku D, Pollonini G, Alberini CM (2012)
Glucocorticoid receptors recruit the CaMKIIalpha-BDNF-CREB
pathways to mediate memory consolidation. Nat Neurosci 15:
1707–1714

Cheung J, Bryant RA (2015) FKBP5 risk alleles and the development of intrusive memories. Neurobiol Learn Mem 125:258–264

Clay R, Hebert M, Gill G, Stapleton LA, Pridham A, Coady M, Bishop J,
Adamec RE, Blundell JJ (2011) Glucocorticoids are required for
extinction of predator stress-induced hyperarousal. Neurobiol
Learn Mem 96:367–377

Coluccia D, Wolf OT, Kollas S, Roozendaal B, Forster A, de Quervain
DJ (2008) Glucocorticoid therapy-induced memory deficits: acute
versus chronic effects. J Neurosci 28:3474–3478

Colvonen PJ, Glassman LH, Crocker LD, Buttnar MM, Orfh H, Schieher
DM, Norman SB, Afari N (2017) Pretreatment biomarkers predicting PTSD psychotherapy outcomes: a systematic review.
Neurosci Biobehav Rev 75:140–156

Conboy L, Sandi C (2010) Stress at learning facilitates memory formation by regulating AMPA receptor trafficking through a glucocorticoid
action. Neuropsychopharmacology 35:674–685

Cordero MI, Kruyt ND, Merino JJ, Sandi C (2002) Glucocorticoid in-
volvement in memory formation in a rat model for traumatic
memory. Stress 5:73–79

Cornelisse S, van Stegeren AH, Joels M (2011) Implications of psycho-
social stress on memory formation in a typical male versus female
student sample. Psychoneuroendocrinology 36:569–578

Cusack K, Jonas DE, Forneris CA, Wines C, Sonis J, Middleton JC,
Feltner C, Brownley KA, Olmsted KR, Greenblatt A, Weil A,
Gaynes BN (2016) Psychological treatments for adults with post-
traumatic stress disorder: a systematic review and meta-analysis.
Clin Psychol Rev 43:128–141

Datson NA, van der Perk J, de Kloet ER, Vreugdenhil E (2001)
Identification of corticosteroid-responsive genes in rat hippocampus
using serial analysis of gene expression. Eur J Neurosci 14:675–689
de Bitencourt RM, Pamplona FA, Takahashi RN (2013) A current overview of cannabinoids and glucocorticoids in facilitating extinction of averse memories: potential extinction enhancers. Neuropharmacology 64:389–395
de Kloet ER, Oitzl MS, Joels M (1999) Stress and cognition: are corticosteroids good or bad guys? Trends Neurosci 22:422–426
de Quervain DJ, Roozendaal B, McGaugh JL (1998) Stress and glucocorticoids impair retrieval of long-term spatial memory. Nature 394:787–790
de Quervain DJF, Aerni A, Schelling G, Roozendaal B (2009) Glucocorticoids and the regulation of memory in health and disease. Front Neuroendocrinol 30:358–370
de Quervain DJ, Bentz D, Michael T, Bolt OC, Wiederhold BK, Margraf J, Wilhelm FH (2011) Glucocorticoids enhance extinction-based psychotherapy. Proc Natl Acad Sci U S A 108:6621–6625
De Quervain DJ, Schwabe L, Roozendaal B (2017) Stress, glucocorticoids and memory: implications for treating fear-related disorders. Nat Rev Neurosci 18:7–19
Delahanty DL, Raimonde AJ, Spooner E (2000) Initial posttraumatic urinary cortisol levels predict subsequent PTSD symptoms in motor vehicle accident victims. Biol Psychiatry 48:940–947
Delahanty DL, Gabert-Quillen C, Ostrowski SA, Nugent NR, Fischer B, Morris A, Pitman RK, Bon J, Fallon W (2013) The efficacy of initial hydrocortisone administration at preventing posttraumatic distress in adult trauma patients: a randomized trial. CNS Spectr 18:103–111
Deschaux O, Zheng X, Lavigne J, Nachon O, Cleren C, Moreau JL, Garcia R (2013) Post-extinction fluoxetine treatment prevents stress-induced reemergence of extinguished fear. Psychopharmacology 225:209–216
Di S, Igoa CA, Fisher MO, Solomonow J, Rottsch EA, Gilpin NW, Tasker JG (2016) Acute stress suppresses synaptic inhibition and increases anxiety via endocannabinoid release in the basolateral amygdala. J Neurosci 36:8461–8470
Domes G, Heinrichs M, Rimmele U, Reichwald U, Hautzinger M (2004) Acute stress impairs recognition for positive words—association with stress-induced cortisol secretion. Stress 7:173–181
Evanson NK, Tasker JG, Hill MN, Hillard CJ, Herman JP (2010) Fast feedback inhibition of the HPA axis by glucocorticoids is mediated by endocannabinoid signaling. Endocrinology 151:4811–4819
Flood JD, Vidal D, Bennett EL, Orme AE, Vasquez S, Jarvik ME (1978) Memory facilitating and anti-amnesic effects of corticosteroids. Pharmacol Biochem Behav 8:81–87
Hamacher-Dang TC, Uengoe M, Wolf OT (2013) Stress impairs retrieval of extinguished and unexaggerated associations in a predictive learning task. Neurobiol Learn Mem 104(1–8):1–8
Hamacher-Dang TC, Merz CJ, Wolf OT (2015) Stress following extinction learning leads to a context-dependent return of fear. Psychophysiology 52:489–498
Hauer D, Weis F, Papassotriopoulos A, Schmoeckel M, Beiras-Fernandez A, Lieke J, Kaufmann I, Kirchhoff F, Vogeser M, Roozendaal B, Briegel J, de Quervain D, Schelling G (2011) Relationship of a common polymorphism of the glucocorticoid receptor gene to traumatic memories and posttraumatic stress disorder in patients after intensive care therapy. Crit Care Med 39:643–650
Henzen C, Suter A, Lerk E, Urbinelli R, Schorno XH, Briner VA (2000) Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet 355:542–545
Hermans EJ, Henckens MJ, Joels M, Fernandez G (2014) Dynamic adaptation of large-scale brain networks in response to acute stressors. Trends Neurosci 37:304–314
Het S, Ramlow G, Wolf OT (2005) A meta-analytic review of the effects of acute cortisol administration on human memory. Psychoneuroendocrinology 30:771–784
Hill MN, Karatsoreos IN, Hillard CJ, McEwen BS (2010) Rapid elevations in limbic endocannabinoid content by glucocorticoid hormones in vivo. Psychoneuroendocrinology 35:1333–1338
Hinkelmann K, Wingenfeld K, Kuehl LK, Freisler J, Heuser I, Wiedemann K, Ott C (2015) Stimulation of the mineralocorticoid receptor improves memory in young and elderly healthy individuals. Neurobiol Aging 36:919–924
Holbrook TL, Galameau MR, Dye J, Quinn K, Dougherty AL (2010) Morphine use after combat injury in Iraq and post-traumatic stress disorder. New Engl J Med 362:110–117
Insel TR, Cuthbert BN (2015) Medicine. Brain disorders? Precisely. Science 348:499–500
Ipser J, Seedat S, Stein DJ (2006) Pharmacotherapy for post-traumatic stress disorder—a systematic review and meta-analysis. S Afr Med J 106(8):1088–1096
Jetly R, Heber A, Fraser G, Boisvert D (2015) The efficacy of nabilone, a synthetic cannabinoid, in the treatment of PTSD-associated nightmares: a preliminary randomized, double-blind, placebo-controlled cross-over design study. Psychoneuroendocrinology 51:585–588
Joëls M, Baram TZ (2009) The neuro-symphony of stress. Nat Rev Neurosci 10:459–466
Joëls M, Sarabdjitsingh RA, Karst H (2012) Unraveling the time domains of corticosteroid hormone influences on brain activity: rapid, slow, and chronic modes. Pharmacol Rev 64:901–938
Johnson LR, Farb C, Morrison JH, McEwen BS, LeDoux JE (2005) Localization of glucocorticoid receptors at postsynaptic membranes in the lateral amygdala. Neuroscience 136:289–299
Kano M (2014) Control of synaptic function by endocannabinoid-mediated retrograde signaling. Proc Jpn Acad Ser B Phys Biol Sci 90:235–250
Karst H, Joëls M (2016) Severe stress hormone conditions cause an extended window of excitability in the mouse basolateral amygdala. Neuropharmacology 110:175–180
Karst H, Berger S, Turault M, Tronche F, Schutz G, Joëls M (2005) Mineralocorticoid receptors are indispensable for nongenomic modulation of hippocampal glutamate transmission by corticosterone. Proc Natl Acad Sci U S A 102:19204–19207
Kelley AE (2004) Memory and addiction: shared neural circuitry and molecular mechanisms. Neuron 44:161–179
Kinner VL, Merz CJ, Lissek S, Wolf OT (2016) Cortisol disrupts the neural correlates of extinction recall. Neuroimage 133:233–243
Kinner VL, Wolf OT, Merz CJ (2018) Cortisol increases the return of fear by strengthening amygdala signaling in men. Psychoneuroendocrinology 91:79–85
Kirschbaum C, Wolf OT, May M, Wippich W, Hellhammer DH (1996) Stress- and treatment-induced elevations of cortisol levels associated with impaired declarative memory in healthy adults. Life Sci 58:1475–1483
Kirschbaum C, Kudielka BM, Gaab J, Schommer NC, Hellhammer DH (1999) Impact of gender, menstrual cycle phase, and oral contraceptive therapy on the activity of the hypothalamus-pituitary-adrenal axis. Psychosom Med 61:154–162
Klengel T, Mehta D, Anacker C, Rex-Haffner M, Pruessner JC, Pariente CM, Pace TW, Mercer KB, Mayberg HS, Bradley B, Nemeroff CB, Holstege F, Heim CM, Ressler KJ, Rein T, Binder EB (2013) Allele-specific FKBP5 DNA demethylation mediates gene-childhood trauma interactions. Nat Neurosci 16:33–41
Kok L, Hillegers MH, Veldhuijzen DS, Cornelisse S, Nierich AP, van der Maaten JM, Roosel PM, Hofland J, Sep MS, Dielemman JM, Vinkers CH, Peelen LM, Joels M, van Dijk D, Dexamethasone for Cardiac Surgery Study G (2016) The effect of dexamethasone on symptoms of posttraumatic stress disorder and depression after cardiac surgery.
Nakataki M, Soravia LM, Schwab S, Horn H, Dierks T, Strik W, West R, Heinrichs M, de Quervain DJ, Feder Spielberg A, Morishima Y (2017) Glucocorticoid administration improves aberrant fear-processing networks in spider phobia. Neuropsychopharmacology 42:485–494

Neumeister A, Normandin MD, Pietrzak RH, Piomelli D, Zheng MQ, Gujarro-Anton A, Potenza MN, Bailey CR, Lin SF, Najafzadeh S, Ropchan J, Henry S, Corsi-Travali S, Carson RE, Huang Y (2013) Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol Psychiatry 18:1034–1040

Ohno-Shosaku T, Kano M (2014) Endocannabinoid-mediated retrograde modulation of synaptic transmission. Curr Opin Neurobiol 29:1–8

Oitzl MS, de Kloet ER (1992) Selective corticosteroid antagonists modulate specific aspects of spatial orientation learning. Behav Neurosci 106:62–71

Okuda S, Roozendaal B, McGaugh JL (2004) Glucocorticoid effects on object recognition memory require training-associated emotional arousal. Proc Natl Acad Sci U S A 101:853–858

Pitman RK, Sanders KM, Zusman RM, Healy AR, Cheema F, Lasko NB, Cahill L, Orr SP (2002) Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biol Psychiatry 51:189–192

Pitman RK, Rasmusson AM, Koenen KC, Shin LM, Orr SP, Gilbertson MW, Milad MR, Liberzon I, Liu SY (2012) Biological studies of post-traumatic stress disorder. Nat Rev Neurosci 13:769–787

Preller KH, Wagner M, Sulzbach C, Hoeing K, Neubauer J, Franke PE, Petrovsky N, Frommann I, Rehme AK, Quednow BB (2013) Sustained incentive value of heroin-related cues in short- and long-term abstinent heroin users. Eur Neuropsychopharmacol 23:1270–1279

Preuss D, Wolf OT (2009) Post-learning psychosocial stress enhances consolidation of neural stimuli. Neurobiol Learn Mem 92:318–326

Putman P, Roelofs K (2011) Effects of single cortisol administrations on human affect reviewed: coping with stress through adaptive regulation of automatic cognitive processing. Psychoneuroendocrinology 36:439–448

Quirarte GL, Roozendaal B, McGaugh JL (1997) Glucocorticoid enhancement of memory storage involves noradrenergic activation in the basolateral amygdala. Proc Natl Acad Sci U S A 94:14048–14053

Quirk GJ, Mueller D (2008) Neural mechanisms of extinction learning and retrieval. Neuropsychopharmacology 33:56–72

Rao CM, Brignoni-Perez E, Goldman R, Phelps EA (2014) Acute stress impairs the retrieval of extinction memory in humans. Neurobiol Learn Mem 112:212–221

Ressler KJ (2018) Alpha-adrenergic receptors in PTSD. Neurosci Biobehav Rev 106:62

Reul JM, de Kloet ER (1985) Two receptor systems for corticosterone in rat brain: microdistribution and differential occupation. Endocrinology 117:2505–2511

Reul JM, van den Bosch FR, de Kloet ER (1987) Differential response of type I and type II corticosteroid receptors to changes in plasma steroid level and circadian rhythmicity. Neuroendocrinology 45:407–412

Riedemann T, Patchev AV, Cho K, Almeida OF (2010) Corticosteroids: way upstream. Mol Brain 3:2

Rimmele U, Besedovsky L, Lange T, Born J (2013) Blocking mineralo-corticoid receptors impairs, blocking glucocorticoid receptors enhances memory retrieval in humans. Neuropsychopharmacology 38:884–894

Roberts S, Keers R, Lester KJ, Coleman JR, Breen G, Arndt K, Blatter-Meunier J, Cooper P, Creswell C, Fjernestad K, Hawik OE, Herren C, Hogenoom SM, Hudson JL, Krause K, Lynham HJ, Morris T, Nauta M, Rapey RM, Roy Y, Schneider S, Schneider SC, Silverman WK, Thustum M, Thirlwall K, Waite P, Eley TC, Wong CC (2015) Hpa axis related genes and response to psychological therapies: genetics and epigenetics. Depress Anxiety 32:861–870

Robinson TE, Berridge KC (2000) The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction 95(Suppl 2): S91–S117

Roitman P, Mechoulam R, Cooper-Kazaz R, Shalev A (2014) Preliminary, open-label, pilot study of add-on oral Delta9-tetrahydrocannabinol in chronic post-traumatic stress disorder. Clin Drug Invest 34:587–591

Roozendaal B (2000) 1999 Curt P. Richter award. Glucocorticoids and the regulation of memory consolidation. Psychoneuroendocrinology 25:213–238

Roozendaal B, McGaugh JL (1996) Amygdaloid nuclei lesions differentially affect glucocorticoid-induced memory enhancement in an inhibitory avoidance task. Neurobiol Learn Mem 65:1–8

Roozendaal B, McGaugh JL (1997) Glucocorticoid receptor agonist and antagonist administration into the basolateral but not central amygdala modulates memory storage. Neurobiol Learn Mem 67:176–179

Roozendaal B, McGaugh JL (2011) Memory modulation. Behav Neurosci 125:797–824

Roozendaal B, Nguyen BT, Power AE, McGaugh JL (1999a) Basolateral amygdala noradrenergic influence enables enhancement of memory consolidation induced by hippocampal glucocorticoid receptor activation. Proc Natl Acad Sci U S A 96:11642–11647

Roozendaal B, Williams CL, McGaugh JL (1999b) Glucocorticoid receptor activation in the rat nucleus of the solitary tract facilitates memory consolidation: involvement of the basolateral amygdala. Eur J Neurosci 11:1317–1323

Roozendaal B, Hahn EL, Nathan SV, De Quervain DJ, McGaugh JL (2004) Glucocorticoid effects on memory retrieval require concurrent noradrenergic activity in the hippocampus and basolateral amygdala. J Neurosci 24:8161–8169

Roozendaal B, Okuda S, van der Zee EA, McGaugh JL (2006) Glucocorticoid enhancement of memory requires arousal-induced noradrenergic activation in the basolateral amygdala. Proc Natl Acad Sci U S A 103:6741–6746

Roozendaal B, McEwen BS, Chattarji S (2009) Stress, memory and the amygdala. Nat Rev Neurosci 10:423–433

Roozendaal B, Hernandez A, Cabrera SM, Hagewoud R, Malvaez M, Stefanko DP, Haettig J, Wood MA (2010) Membrane-associated glucocorticoid activity is necessary for modulation of long-term memory via chromatin modification. J Neurosci 30:5037–5046

Sajadi AA, Samaei SA, Rashidy-Pour A (2006) Intra-hippocampal microinjections of anisomycin did not block glucocorticoid-induced impairment of memory retrieval in rats: an evidence for non-genomic effects of glucocorticoids. Behav Brain Res 173:158–162

Sandi C (2011) Glucocorticoids act on glutamatergic pathways to affect memory processes. Trends Neurosci 34:165–176

Sandi C, Pino-Le Nava MT (2007) Stress and memory: behavioral effects and neurobiological mechanisms. Neural Plast 2007:78970

Sandi C, Rose SP (1994) Corticosterone enhances long-term retention in one-day-old chicks trained in a weak passive avoidance learning paradigm. Brain Res 647:106–112

Sapolsky RM (2000) Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 57:925–935

Sapolsky RM, Romero LM, Munck AU (2000) How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev 21:55–89

Schelling G, Briegel J, Roozendaal B, Stoll C, Rotenstein HB, Kapfhammer HP (2001) The effect of stress doses of hydrocortisone during septic shock on posttraumatic stress disorder in survivors. Biol Psychiatry 50:978–985

Schelling G, Kilger E, Roozendaal B, De Quervain DJ, Briegel J, Dagge A, Rotenstein HB, Krauseneck T, Nollett G, Kapfhammer HP (2004) Stress doses of hydrocortisone, traumatic memories, and...
trial showing improved treatment retention and outcome.
Psychoneuroendocrinology 51:589–597
Zannas AS, Wiechmann T, Gassen NC, Binder EB (2016) Gene-
stress-epigenetic regulation of FKBP5: clinical and transla-
tional implications. Neuropsychopharmacology 41:261–274
Zhou M, Hoogenraad CC, Joëls M, Krugers HJ (2012) Combined
beta-adrenergic and corticosteroid receptor activation regu-
lates AMPA receptor function in hippocampal neurons. J
Psychopharmacol 26:516–524
Zohar J, Yahalom H, Kozlovsky N, Cwikel-Hamzany S, Matar
MA, Kaplan Z, Yehuda R, Cohen H (2011) High dose hy-
drocortisone immediately after trauma may alter the trajectory
of PTSD: interplay between clinical and animal studies. Eur
Neuropsychopharmacol 21:796–809